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From the Wepartment of Biochemistry and Molecular Genetics, Schools of Medicine and Dentistry, University of Alabama
at Birmingham, Birmingham, Alabama 35294 and liThe Brookdale Center for Molecular Biology and Department of
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Erythroid Kruppel-like factor (EKLF) is an erythroidspecific transcription factor that contains zinc finger
domains similar to the Kruppel protein of Drosophila
melanogaster, Previous studies demonstrated that
EKLF binds to the CACCC box in the human p-globin
gene promoter and activates transcription. CACCC box
mutations that cause severe p-thalassemias in humans
inhibit EKLF binding. Results described in this paper
suggest that EKLF functions predominately in adult
erythroid tissue. The EKLF gene is expressed at a 3-fold
higher level in adult erythroid tissue than in fetal erythroid tissue, and the EKLF protein binds to the human
p-globin promoter 8-fold more efficiently than to the
human 'Y-globin promoter. Co-transfection experiments
in the human fetal-like erythroleukemia cell line K562
demonstrate that over-expression of EKLF activates a
p-globin reporter construct lOOO-fold; a linked 'Y-globin
reporter is activated only 3-fold. Mutation of the p-globin CACCC box severely inhibits activation. These results demonstrate that EKLF is a developmental stageenriched protein that preferentially activates human
p-globin gene expression. The data strongly suggest that
EKLF is an important factor involved in human 'Y- to
p-globin gene switching.

All vertebrate animals switch hemoglobins during development. In humans, the first site of erythropoiesis is the yolk sac
blood islets. Erythroid cells in the yolk sac are formed from
embryonic mesoderm at approximately 3 weeks of gestation.
The first hemoglobins produced by these cells are tetramers
composed of2 ~-globin
or 2 a-globin polypeptides and 2 E-globin
polypeptides. The hemoglobins are designated Gower I (~2E2)
and Gower II (a2E2)' ~-Globin
gene expression gradually decreases and a-globin expression gradually increases over the
next few weeks until Gower II (a2E2) is the predominate hemoglobin. At approximately 5 weeks of development, hematopoietic stem cells from the yolk sac migrate to the fetal liver and
initiate hematopoiesis in this organ. Fetal liver then becomes
the major site of erythropoiesis, and there is a concomitant
switch in hemoglobin production; E-Globin gene expression de-
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creases, and the fetal y-globin gene is activated. The major
hemoglobin produced at this stage of development is, therefore,
fetal hemoglobin (a 2Y2)' Finally, hematopoietic stem cells from
the fetal liver migrate to the bone marrow. This organ then
becomes the major site of erythropoiesis, and there is a final
switch in hemoglobin synthesis. Expression of the y-globin
gene steadily decreases, and expression of the S- and f3-g10bin
genes gradually increase until approximately 98% of total hemoglobin is hemoglobin A (a 2f3 2) and approximately 1% is hemoglobin A2 (a 2S2); the S-globin promoter is enfeebled and,
therefore, is transcribed poorly. The y-globin gene continues to
be transcribed in a minor population of erythroid cells that
develop in the adult bone marrow; these cells are designated F
cells, and the HbF in these cells accounts for approximately 1%
of total hemoglobin in adult blood (1).
The molecular mechanisms that direct hemoglobin switching
during development are almost completely unknown. In humans, a powerful regulatory sequence designated the locus
control region (LCR)1 is located far upstream of the f3-g10bin
locus on chromosome 11 (for review, see Refs. 2-5)). The f3-g10bin LCR has two important functions. First, these sequences
open a chromosomal domain that extends over 200 kb. This
chromatin decondensation renders individual genes in the locus more accessible to trans-acting factors that control temporal specific expression. Secondly, the LCR acts as a master
enhancer; individual globin gene family members compete for
interactions with the LCR to determine which genes are expressed at specific developmental stages. Positive and negative
regulatory factors that bind to specific globin gene promoters
and proximal enhancers or silencers provide individual genes
with a competitive advantage or disadvantage for interaction
with the LCR. Once interactions between a particular globin
genets) and the LCR is established, the complex is relatively
stable and commits this chromosomal allele(s) to express E, Gy,
and Ay or S- and f3-g10bin throughout the lifetime of the cell.
Although developmental stage-specific factors have been
proposed to regulate globin gene expression during development, no proteins that control human y- to f3-g10bin gene
switching have been identified. In this paper, we have examined the role of erythroid Kruppel-like factor (EKLF) in globin
gene switching. EKLF is an erythroid cell-specific transcriptional activator that contains three zinc fingers homologous to
the Kruppel family of transcription factors (6). As shown by
crystallographic and "finger-swapping" experiments with other
members of this family, each finger contacts 3 base pairs, such
that the binding site for the EKLF protein was predicted to be
3'-GGNGNGGGN-5'. Based on this information, it was dem1 The abbreviations used are: LCR, locus control region; EKLF,
Erythroid Kruppel-like factor; kb, kilobaseis); Luc, luciferase; CAT,
chloramphenicol acetyltransferase; ylLuc, v-globin/Luc; f3-CAT, f3-globin/CAT; HS 2, hypersensitive site 2.
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onstrated that EKLF binds to and mediates its transcriptional
activation via the human and murine adult f3-globin CAC site
(5' -CCACACCCT-3') (6), a site known to be critical for f3-globin
expression (7-10). Methylation interference studies indicated
that EKLF forms close contacts to each of the guanine residues
within this extended 9-base pair site, such that point mutation
of some of these residues, including those that give rise to
f3-thalassemia, drastically disrupt binding (11). These results
suggest that EKLF may be intimately involved in the regulation of globin expression through its interaction with the
CACCC element.
However, inspection of CAC-related sequences in other murine and human f3-globin promoters in the context of the complete 9-base pair EKLF-binding element reveals that these
sites do not form a homogeneous group. Of particular interest
for the present study is the sequence 5' -CTCCACCCA-3' in the
human fetal Ay- and Gv-globin promoter (and in the murine
embryonic y-globin promoter). This sequence contains a mismatch to the predicted EKLF binding site, i.e. binding by the
EKLF amino-terminal finger to 5'-CCN-3'. Our previous studies have emphasized the importance of interactions by specific
nucleotides in the complete f3-CAC site with critical EKLF
amino acid residues (6, 11). A decrease in EKLF binding affinity to the variant y-CAC site could playa major role in determining the relative levels of '1- and f3-globin transcription. We
have therefore directly tested the ability of EKLF to bind to the
'I-globin CAC site in vitro and have examined the role ofEKLF
in human '1- to f3-globin gene switching in vivo.
MATERIALS AND METHODS

Competitive Gel Shift Assays-The competitive gel shift assays were
performed as described (6,11). The presence ofa doublet in the gel shift
experiments results from the production of different size glutathione
S-transferase-EKLF fusion proteins in the preparation as described by
Miller and Bieker (6).
Northern Blot Hybridizations-Northern blot hybridizations were
performed as previously described (12). The EKLF probe was a 0.74-kb
StuI-PvuI fragment of the EKLF cDNA; this probe lacks the zinc finger
coding region. The mouse a-globin probe was a 1.1-kb ApaI-XhoI fragment, which contains the entire genomic clone.
Plasmid Constructions-The construction of the HS 2-ylluciferase
reporter has been described (12). HS 2-{3lluciferase was constructed
similarly to HS 2-ylluciferase. A SnaBI-NcoI fragment that contained
human {3-globin promoter and 5'-untranslated sequences from -265 to
+48 was blunted with Sl nuclease and inserted into a blunted BglII site
between HS 2 and luciferase in the HS 2ILuc plasmid (12).
HS 2-ylluciferase-{3/CAT was constructed in several steps. {3/CAT
was made by inserting the blunt-ended {3-globin promoter fragment
described above into the plasmid pCAT-Basic (Promega), which had
been cut withXbaI and blunted with Klenow polymerase. The following
three fragments were then ligated to make HS 2-ylluciferase-{3/CAT: a
4.5-kb KpnI-SalI fragment from HS 2-ylluciferase containing HS 2, the
y-globin promoter, the luciferase gene, and the SV40 splice and polyadenylation signals; a 2.0-kb SalI-BamHI {3/CAT fragment containing
the (3-promoter, CAT gene, and splice and poly(A) signals; and a 2.9-kb
BamHI-KpnI fragment from pGL2-Basic (Promega) containing prokaryotic vector sequences.
To construct HS 2 (CACCCsCr)-ylluciferase-{3/CAT, a mutant HS 2
fragment containing the scrambled CACCC motif was derived from a
previously described plasmid (13) (plasmid 5' -HS 2 (K-P) (38689-98s)).
The 1.4-kb KpnI-StuI HS 2 fragment from this mutant plasmid was
used to replace the corresponding wild type region in HS 2-ylluciferase{3/CAT.
To make HS 2-ylluciferase-{3 (-87)/CAT, a {3-promoter containing the
-87 G to C {3-thalassemia mutation was constructed using the megaprimer mutagenesis method (14-16). The outside primers overlapped
the SnaBI site at -265 and the NcoI site at +48 of the human {3-promoter. The 3' -primer changed the Ncol site to a SnaBI site (underlined
in the sequence below) so that a blunt end promoter fragment could be
easily prepared. The template was a linearized HinfI subclone of the
human (3-promoter in pUC 19. Primers used to amplify the mutant
promoter were 1) the upstream pUC reverse primer from New England
Biolabs, 2) the mutagenic oligonucleotide 5' -CCTGGGAGTAGATTG-

GCCAACCCTAGQGTGTGGCTCCACAGGGTGAGGTCTAAGT-3' (the
mutated base is underlined), and 3) the downstream oligonucleotide
5'-AGGTGCACCTACGTATCGGTTTGAGGTTGCTAGTG-3' (the underlined bases represent a SnaBI site). The resulting SnaBI fragment
containing the (3 (-87) mutation was used to make HS 2-ylluciferase-{3
(-87)/CAT as described for the wild type plasmid. All promoter sequences were verified by dideoxy sequencing (17) using the Sequenase
kit (U. S. Biochemicals Corp.).
Transactivation Analysis-Co-transfections and reporter gene assays were performed as described (12), except that luciferase assays
were measured on a Turner model 20 luminometer (Promega) using the
Promega Luciferase Assay System. Extracts were diluted 1:10 for luciferase assays (20 f.L! of diluted extract assayed for all samples), and
representative values were in the range of 600 light units/ul of extractJ
{3-galactosidase A 4 20 for vector controls and 1,800 light units!f.LI of extractJ{3-galactosidase A 4 20 for EKLF co-transfections (linear range,
-0.1-10,000). For CAT assays, vector control extracts were assayed
undiluted (50 f.LI of extract), and EKLF co-transfection extracts were
diluted up to 200-fold for assays. For the wild type HS 2-ylluciferase{3/CAT reporter, representative values obtained were on the order of 50
cpm/ f.LI of extractJ{3-galactosidase A 4 2 0 in vector controls and about
50,000 cpm/ul of extractJ{3-galactosidase A 4 2 0 for EKLF co-transfections
(minimum detectable activity was 10 cpm/ul of extractJ{3-galactosidase
A 4 2 0 or 5-fold over background under these assay conditions).
RESULTS

Fig. 1A illustrates a competitive gel shift experiment designed to measure the relative binding efficiency of EKLF to
the CACCC boxes in the human 13- andy-globin gene promoters. A double-stranded oligonucleotide containing the f3-globin CACCC box was end-labeled and incubated with purified
EKLF (11) in the presence of increasing amounts of unlabeled
13- andy-globin CAC box oligonucleotides. The results were
quantitated and graphed as illustrated in Fig. lB. Under the
conditions of the assay, an 11-fold excess of f3-globin CAC site
was required to inhibit the EKLF-CAC shift by 50%; however,
a 90-fold excess of the 'I-globin CAC site was required for 50%
inhibition. These results demonstrate that EKLF binds approximately 8-fold more efficiently to the f3-globin CACCC box than
to they-globin CACCC box; this is consistent with the very
weak EKLF/y-CAC gel shift that is observed relative to that
seen with EKLF/f3-CAC (Fig. Ie). The higher binding affinity of
EKLF to adult versus fetal globin gene promoters suggests that
EKLF may be involved in '1- to f3-globin gene switching.
The level of EKLF expression in fetal and adult erythroid
tissue was also examined. Fig. 2 illustrates a Northern blot of
mouse yolk sac, fetal liver, and reticulocyte RNA probed with
the murine EKLF cDNA clone. The filter was subsequently
stripped and reprobed with a mouse a-globin clone as a control.
Bands were quantitated on a phosphorimager, and EKLF expression was normalized to a-globin expression. The results
demonstrate that EKLF expression in mouse fetal liver, which
is an adult erythroid tissue, is 3-fold higher than expression in
mouse yolk sac. The switch from embryonic/fetal globin to adult
globin gene expression in the mouse occurs when the site of
erythropoiesis shifts from yolk sac to fetal liver at approximately 14 days of development; adult globin expression is then
maintained when bone marrow becomes the major site of erythropoiesis at birth. The higher levels of EKLF mRNA in adult
compared with fetal tissue also suggest that EKLF may be
involved in 'I- to f3-globin switching.
To determine the functional consequences of differential EKLF
binding to human y- and f3-globin gene promoters, co-transfection
experiments in K562 cells were performed. These cells normally
synthesize little EKLF (Fig. 2), and no f3-globin mRNA can be
detected (data not shown). y-Globin/luciferase (y/Luc) and f3-globin/CAT (f3/CAT) reporter genes were inserted downstream of the
LCR HS 2 (18) (Fig. 3A), and these constructs were co-transfected
with an EKLF expression vector into K562 cells. Fig. 3B demonstrates that EKLF stimulates y/Luc expression only 3-fold; how-
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FIG. 1. Co m peti t ive gel r etardation a n a lysis of EKLF b inding to varian t CAC si te-con taining oligo n u cleotides in vitro. Gel shift
assays used rad iolabeled adul t /3-globin oligonucleoti des a nd th e indicated non-r adi oactiv e compet itor oligonu cleoti des at 0-, 20-, 50-, 100-, 200-,
and 400-fold molar excess (lanes 2-7, resp ectively). Lane 1 contained no protein added to the incubation. Data for two preparations of pu ri fied
EKLF a re shown to demonstra te the re producibility of th e assay . Th e autora diogra ph of the gel resul ting from all the assays is shown in A , and
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EKLF ' "

a -globin . . .

12 3 4 5 6
F IG. 2. No r t hern b lot anal ysi s of EKLF a n d m ou se a- glob in
e xp r ession . Lanes 1- 6 were load ed wit h 2 p.g of total RNA from the
indicated cell lines a nd tiss ues . La ne 1, human eryth roleukemia cells
(K562); lane 2, mouse eryth role ukemia cells uninduced (MEL -UJ; lan e
3, mouse erythroleuke mia cells in duced with 1.5% dim eth yl sulfoxide
for 3 days (MEL-!); lane 4, yolk sacs dissected from 1O.5-day -old mouse
embryos (10.5 d YS ); lane 5, fetal liver dissected from 16-day-old mouse
fetuses (16 d FL ); lane 6, a dult blood from phenylh ydraz ine-tr eated
mice (Ad . Blood ). Ph osph orim ager quan titat ion of bands (Molecula r
Dyn ami cs Ph osph orimager ) shows th at the level of EKLF message/a globin message is 3-fold h igher in 16 d FL tha n in 10.5 d YS. A fa in t
band of EKLF a nd a -globin mRNA is observed in the K562 la ne a fter
longer exposure (data not shown ).

ever , {3/CAT expression is stimulated 3D-fold (Fig. 38). Th ese
results demonstrate that EKLF prefere ntially activates {3-globin
gene expression, an d the data suggest that preferential binding
of EKLF to the {3-globin gene CACCC box is at least partially
res ponsi ble for this effect.
Competition models for human y- to {3-globin gene switchi ng

predict that t he re are adult-specific or adult-enriche d positive
regulatory factors th at bind to the {3-globin gene a nd give this
gen e a preferen tial adva ntag e to form interactions wit h th e
LCR. The LCR the n enhances high level expression of the
{3-globin gene specifically in adult erythro id cells. To te st t he
effect of EKLF on linked y- a nd {3-globin genes, we co-transfected K562 cells with an EKLF expression vector an d a construct containing y/Luc an d {3/CAT reporters inserted downstream ofLCR HS 2 (HS 2 y/Luc-{3/CAT) Fig. 4A ). Aga in , EKLF
expression stimulate d th e y-globin prom oter only 3-fold; however , the {3-globin promoter was enhanced 1,000-fold (Fig. 4B ).
Th ese da ta suggest th at EKLF binding to the {3-globin CACCC
box ma y play a critical role in human y- to {3-globin gen e
swit ching. When t he HS 2 y/Luc-{3/CAT construct was t rans fected into Hela cells wit h a nd wit hout the EKLF expression
vector, no enhancement of v: or {3-reporter expre ssion by EKLF
was observed (dat a not shown).
As described ab ove, a mu tation at -87 (CACCC to CACGC)
in t he {3-globin prom oter inhibits {3-globin gene expr ession and
causes {3-thalassemia in human s (19, 20). This -87 mutation
was introduced into the {3-globin gene promoter in the linked
y/Luc-{3/CAT reporter construct , and the plasmid was co-transfect ed with the EKLF expression vector into K562 cells . The
data in Fig . 5 demonst rate that t he -87 mutation strongly
inhibit s EKLF activation of the {3-globin gene (1000 to 4-fold
activation). Mutation of the ph ylogen eti cally conserve d CACCC
box (21) located app roxim ately 15 base pair s downstream of the
Ap l -like sites in HS 2 also decreases {3-globin gene activa tion
(1000 to 730-fold activation ).
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Models of human globin gene switching postulate that developmental stage-specific transcription factors bind to promoters
and proximal enhancers or silencers and influence the interaction of E-, y-, and j3-globin genes with the powerful LCR. Although these stage-specific proteins have been postulated for
many years, no positive or negative regulatory factors that
direct y. to j3-globin gene switching have been identified. The
data described above strongly suggest that EKLF is a developmental stage-enriched factor that is involved in the switch from
human y-globin to j3-globin gene expression. The binding affinity of EKLF is 8-fold higher for the j3-globin promoter than for
the y-globin promoter (Fig. 1), and the EKLF gene is expressed
at a 3-fold higher level in adult erythroid tissue than in fetal
erythroid tissue (Fig. 2). Although we have not yet quantitated
EKLF protein in these cells, Northern blot data (Fig. 2) suggest
that EKLF levels in adult erythroid tissue are significantly
higher than in fetal erythroid tissue. To determine the functional consequences of differential EKLF concentration and
binding affinity, we co-transfected an EKLF expression vector
with HS 2 ylLuc and HS 2 j3-/CAT reporter constructs into
K562 cells. These fetal-like erythroleukemia cells express ybut not j3-globin genes and normally synthesize little EKLF
(Fig. 2). After transfection, v-Luc was activated only 3-fold, but
j3/CAT was activated 30-fold (Fig. 3). When ylLuc and j3/CAT
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were linked in the same construct (HS 2 ylLuc-j3/CAT) and
co-transfected with the EKLF expression vector into K562
cells, the j3-globin promoter was activated lOOO-fold; the y-glo-
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bin promoter was activated only 3-fold (Fig. 4). Mutation of the
{3-globin CACCC box at -87 (CACCC to CACGC) strongly
inhibited EKLF activation (1000 to 4-fold activation Fig. 5).
These results suggest that EKLF is an important factor in
human )'- to {3-globin gene switching and that the CACCC
boxes are critical elements in this switch. Mutation of the
phylogenetically conserved CACCC site in HS 2 modestly inhibits EKLF activation in transient assays (Fig. 5). Analysis of
this same mutation in transgenic mice shows a similar reduction in activity (13). Reddy et al. (22) recently showed that the
HS 2 CACCC site is footprinted in vivo in adult human erythroblast but not in the fetal environment of K562 cells. These
results, together with the results presented in this paper, suggest that the HS 2 CAC site may also contribute to {3-globin
gene activation.
The lower binding affinity of EKLF for the v-globin CAC site
is not entirely unexpected. Methylation interference demonstrates that EKLF interacts with all the guanine residues on
the G-rich strand of the {3-globin CAC site, including the sequence 3' -GGN-5', which is the putative first finger target site
(11). These studies showed that changes of single guanine
residues had a dramatic effect on EKLF binding affinity to
those variant sites. In the )'-CAC site, the first finger target site
would be 3' -GAG-5', yielding a loss of an important guanine
residue. The lower affinity for this site indicates that binding of
the amino-terminal EKLF zinc finger is an important contributor to the overall affinity of EKLF-CAC site interaction. As a
result, efficient EKLF binding to the CTCCACCCA site present
in the v-globin promoter is very low and may be heavily dependent on the effective EKLF protein concentration or on the
presence of a cofactor. Alternatively, Ikuta and Kan (23) have
demonstrated an in vivo footprint on the )'-CAC box but not on
the (3-CAC box in K562; therefore, transcription of the )'-globin
gene may require another CACCC element-binding factor that
is primarily active in fetal, rather than adult, erythroid cells.
Competition models of globin gene switching predict that
enhanced interaction of one globin gene with the LCR necessarily decreases the interaction of another gene with the LCR.
This mechanism accounts for the precise developmental specificity of globin gene expression. However, in the experiments
described above, both )'- and {3-globin genes were stimulated.
EKLF expression enhanced (3/CAT activity 1000-fold, and
)'lLuc activity did not decrease but increased 3-fold. Stimulation of both genes in this instance may occur because all of the
regulatory factors required for expression of )'- and {3-globin
genes are present at the same time. K562 cells normally contain the factors necessary for v-globin expression, and ectopic
expression of EKLF apparently provides an additional factor
necessary for (3-globin gene activation. Expression of both
genes in the same cell would be the predicted result if the
equilibrium constants for LCR-)' and LCR-{3 interactions are
equivalent when both fetal and adult regulatory factors are
present.
If EKLF was the only positive factor necessary for )'- to
{3-globingene switching, one would predict that overexpression
of this factor in fetal erythroid cells would activate the endogenous {3-globin gene. However, we stably transformed K562
cells with the EKLF expression vector, and no endogenous
{3-globin mRNA was detected. This result suggests that additional factors are required to activate a chromosomal copy of
the adult gene. Although the entire {3-globinlocus appears to be

in an "open" or DNase I-sensitive domain in erythroid cells,
local changes in chromatin structure around individual genes
may play a role in switching. Perhaps additional temporal
specific factors are required to reposition nucleosomes so that
the CACCC boxes are more or less accessible to EKLF (24-26).
Jane et al. (27) recently defined a stage-selector element in
the v-globin promoter that appears to be important in y-globin
gene activation. This sequence is located between -54 and
-35, and insertion of the stage-selector element in a {3-globin
gene construct results in a 10-fold increase in {3-globin gene
expression in K562 cells. A fetal-specific protein complex designated SSP (stage-selector protein) binds to the sequence (28)
and is most likely involved in v-globin gene activation in fetal
development. Therefore, this protein and EKLF may be critical
fetus- and adult-specific proteins that are responsible for human E- to v-globin and y- to (3-globin gene switching during
development.
The results described above strongly suggest that EKLF is
an important factor in temporal control. Targeted mutation of
the EKLF gene in embryonic stem cells should provide additional information on the role of EKLF in hemoglobin switching. Based on the data in this paper, the phenotype of mice that
are homozygous for a mutation in EKLF can be predicted.
These mice should survive through early development but then
die between 12 and 14 days of gestation when the switch from
fetal to adult globin gene expression occurs.
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